复方斑蝥含药血清抑制人肝癌Bel-7402细胞增殖的机制研究

Inhibitory effect of compound mylabris on the proliferation of human hepatocarcinoma cell line Bel-7402 and its molecular mechanism

目的探讨复方斑蝥抑制人肝癌Bel-7402细胞增殖的作用机制。方法血清药理学方法制备复方斑蝥血清并处理人肝癌Bel-7402细胞,MTT方法观察其对人肝癌Bel-7402细胞增殖的抑制作用,RT-PCR技术检测其对c-Myc、p53基因表达的影响。结果复方斑蝥含药血清能够显著抑制Bel-7402细胞的增殖,并下调c-Myc和上调p53基因的表达。结论复方斑蝥可能通过影响细胞增殖相关基因的表达抑制Bel-7402细胞的增殖,可作为一种抗肝癌中药复方的研究原型。

Objective To investigate the molecular mechanism underlying the inhibitory effect of compound mylabris on the proliferation of human hepatocarcinoma cell line Bel-7402. Methods The compound mylabris serum was prepared based on serum pharmacology and was used to treat human hepatocarcinoma cell line Bel-7402. MTF assay was used to evaluate the inhibitory effect of compound mylabris on the proliferation of human hepatocarcinoma cell; RT-polymerase chain reaction （RT-PCR） was used to evaluate c-Myc and p53 mRNA expressions in human Hepatocarcinoma cell Bel-7402. Results Compound mylabris serum can remarkably inhibit the proliferation of human hepatocarcinoma cell line Bel-7402 in which gene c-Myc was down-regulated, while p53 was up-regulated. Conclusion Compound mylabris possibly affects the expressions of genes related to the proliferation of human hepatocarcinoma cell line Bel- 7402. It is indicated that compound myabris can be used as a prototype for compound traditional Chinese medicine against liver cancer.